TP53 co-mutations are associated with elevated PD-L1 expression and high tumor mutational burden in non-small cell lung cancer: insights from comprehensive genomic profiling

Abstract excerpt

Background: Precision oncology in non-small cell lung cancer (NSCLC) requires comprehensive genomic characterization to inform therapeutic decisions. However, the spectrum of genomic alterations and their co-mutation patterns, particularly in relation to immunotherapy biomarkers, remains incompletely understood. This study investigated the associations between driver gene alterations and clinicopathological...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Immunotherapy and Biomarkers
• Share to Cancer-related Molecular Pathways
• Share to Lung Cancer Treatments and Mutations